International patterns of childhood chronic myeloid leukemia: Comparisons between the United States and resource-restricted nations

Pediatric Blood and Cancer

Volumn 61, Issue 10, 2014, Pages 1774-1778

  Sadak, Karim Thomas ^a,b   Fultz, Kara ^c   Mendizabal, Adam ^c,d   Reaman, Gregory ^e,f   Garcia Gonzalez, Pat ^g   Levine, Paul H ^c  

^a University of Minnesota Children's Hospital   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d EMMES CORPORATION   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g The Max Foundation ^*  (United States)

Author keywords

Childhood chronic myeloid leukemia; International cohort survivor

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AFRICA; ARTICLE; ASIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; EUROPE; FEMALE; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; INFANT; INTERNATIONAL RELATIONS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEWBORN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PACIFIC ISLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SOUTH AND CENTRAL AMERICA; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; YOUNG ADULT;

CHILDHOOD CHRONIC MYELOID LEUKEMIA; INTERNATIONAL COHORT SURVIVOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; UNITED STATES; WORLD HEALTH; YOUNG ADULT;

EID: 84908553848     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25120     Document Type: Article

References (20)

1. In Ries LAG, Smith MA, Gurney JG, et al. (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999. NIH Pub. No. 99-4649.
2. American Cancer Society. Cancer facts & figures 2011. Atlanta: American Cancer Society; 2011.
3. Redaelli A, Bell C, Casagrande J, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 2004; 4:85-96.
4. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukemia. The Lancet 2007; 370:342-350.
5. Kantarjian H. Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML experts. Blood 2013; doi: 10.1182/blood-2013-03-490003.
6. Kanavos P, Vandoros S, Garcia-Gonzalez P. Benefits of global partnerships to facilitate access to medicines in developing countries: A multi-country analysis of patients and patient outcomes in GIPAP. Global Health 2009; 5:19.
7. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol 2013; 37:247-254.
8. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2001; 104:2655-2660.
9. United Nations, World Macro Regions and Components [Internet]; 2009; 450 [accessed 15.05.09].
10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub, (1973-2009).
11. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int 494 J Hematol 2009; 89:14-23.
12. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely effects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86:471-474.
13. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes 478 of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009; 113:5401-5411.
14. Narayanan KR1, Bansal D, Walia R, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer 2013; 60:1148-1153.
15. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2009; 27:5175-5181.
16. Andolina JR1, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119:1821-1830.
17. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29:2827-2832.
18. American Cancer Society. Global cancer facts & figures, 2nd edition. Atlanta: American Cancer Society; 2011. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf.
19. Kachroo S1, Etzel CJ. Decreasing the cancer burden in developing countries: Concerns and recommendations. Eur J Cancer Care 2009; 18:18-21.
20. World Health Organization (WHO). 2007a; Cancer: Diet and physical activity's impact. Available at: http://www.who.int/dietphysicalactivity/publications/facts/cancer/en/.